Abstract
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL). Differentiation of MF especially early stages (eMF) from its benign mimickers is important to ensure proper management. TOX is a critical regulator of early T-cell development in the thymus that is considered as a useful marker for MF diagnosis and prognosis. Objective: The aim of the current study is to evaluate the ability of molecular marker TOX protein in diagnosis of eMF, and its ability to differentiate eMF from similar benign inflammatory skin diseases (BIDs). Materials and Methods: This is a case control study, and was carried out on 60 subjects; 20 patients as eMF, 20 patients as (BIDs) and 20 normal skin specimens as control cases. The diagnosis was established after clinicopathological correlation. Immunohistochemistry (IHC) was done for MF, BIDs and normal skin cases for TOX and CD4 IHC stains. Results: TOX expression showed a significant positive expression in MF cases compared to BIDs and control groups, with 100% sensitivity and 95% specificity. The pattern of TOX IHC stain in MF was diffuse, while in BIDs was focal. There was positive correlation between TOX and CD4 staining in MF cases. Conclusion: TOX might be considered a diagnostic marker for eMF that can differentiate eMF from BIDs mimickers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
